Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/
Gene therapy biotech shares sink on inconclusive trial resultsShares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results Share XGene therapy biotech shares sink on inconclusive trial resultshttps://pharmaphorum.com/news/gene-therapy-biotech-shares-sink-on-inconclusive-trial-results/
Sangamo edits living patient’s DNA for first timeDoctors in California have made history by attempting to edit genes within a patient for the first time, Share XSangamo edits living patient’s DNA for first timehttps://pharmaphorum.com/news/us-doctors-gene-editing/
